Patents Represented by Attorney, Agent or Law Firm Kathleen Fowler
  • Patent number: 7648702
    Abstract: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: January 19, 2010
    Assignee: Immunex Corporation
    Inventors: Wayne R. Gombotz, Richard L. Remmele, Jr.
  • Patent number: 7544784
    Abstract: The invention provides methods of increasing yields of desired conformation of proteins. In particular embodiments, the invention includes contacting preparations of a recombinant protein with a reduction/oxidation coupling reagent for a time sufficient to increase the relative proportion of a desired configurational isomer.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: June 9, 2009
    Assignee: Immunex Corporation
    Inventors: Helmut M. Sassenfeld, Richard L. Remmele, Jr., Rebecca E. McCoy
  • Patent number: 7276477
    Abstract: The present invention relates to crystalline etanercept and to methods of making crystalline etanercept; to pharmaceutical compositions comprising crystalline etanercept; and to therapeutic uses of such compositions.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: October 2, 2007
    Assignee: Amgen Inc.
    Inventors: Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass
  • Patent number: 7166445
    Abstract: The invention provides improved methods of recombinant protein production in cell culture. More specifically, the invention relates to the modulation of the IGF-1 signaling pathway in cells so as to improve production characteristics.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: January 23, 2007
    Assignee: Immunex Corporation
    Inventors: Arvia E. Morris, Pranhitha Reddy
  • Patent number: 7157557
    Abstract: The invention provides methods of increasing yields of desired conformation of proteins. In particular embodiments, the invention includes contacting preparations of a recombinant protein with a reduction/oxidation coupling reagent for a time sufficient to increase the relative proportion of a desired configurational isomer.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: January 2, 2007
    Assignee: Immunex Corporation
    Inventors: Helmut M. Sassenfeld, Richard L. Remmele, Jr., Rebecca E. McCoy
  • Patent number: 7101982
    Abstract: The invention provides methods of controlling pH variations during chromatography. In particular embodiments, the invention includes equilibrating and eluting proteins from chromatography resins have a solid phase that possesses a charged functional group on its backbone under controlled conditions of osmolarity and pH. The invention is particularly useful in the purification of proteins that are sensitive to pH transitions such as, for example, the IL-1 Receptor type II protein.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: September 5, 2006
    Assignee: Immunex Corporation
    Inventors: Sanchayita Ghose, Thomas M. McNerney
  • Patent number: 7091004
    Abstract: The invention provides cells that produce increased levels of recombinant protein by modulating the activity of translational regulator gene products that are downstream targets of PKB alpha, methods of making such cells, and methods of using such cells. Such translational regulator gene products include 4E-BP1 and mTOR.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: August 15, 2006
    Assignee: Immunex Corporation
    Inventors: Arvia E. Morris, Sharon T. Wong-Madden
  • Patent number: 6972327
    Abstract: The invention provides improved methods of regenerating and using affinity chromatography material, in particular Protein A affinity chromatography resins.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: December 6, 2005
    Assignee: Immunex Corporation
    Inventors: Hassan Madani, Robert D. Hershberg
  • Patent number: 6924124
    Abstract: The invention is in the field of cell culture, particularly recombinant cell culture. More specifically, the invention relates to methods of fed batch CHO cell culture.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: August 2, 2005
    Assignee: Immunex Corporation
    Inventor: Pankaj Singh
  • Patent number: 6897040
    Abstract: The invention provides improved methods of recombinant protein production in cell culture. More specifically, the invention relates to the modulation of the IGF-1 signaling pathway in cells so as to improve production characteristics.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: May 24, 2005
    Assignee: Immunex Corporation
    Inventors: Arvia E. Morris, Pranhitha Reddy
  • Patent number: 6774224
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: August 10, 2004
    Assignee: Immunex Corporation
    Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
  • Patent number: 6670135
    Abstract: This invention provides a method comprising assaying the binding of a DCSema polypeptide to a VESPR protein.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: December 30, 2003
    Assignee: Immunex Corporation
    Inventor: Melanie K. Spriggs
  • Patent number: 6632637
    Abstract: There is disclosed an expression vector utilizing an internal polyadenylation signal. The internal polyadenylation signal is inserted between a DNA encoding a protein of interest and a DNA encoding a selectable marker, and allows a single promoter to generate both monocistronic messages and dicistronic messages. Similar, multicistronic vectors can also be prepared. Also disclosed are methods of using the expression vector utilizing an internal polyadenylation signal, host cells transfected therewith, stable pools of cells transfected with an expression vector utilizing an internal polyadenylation signal, and clones of such transfected cells.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: October 14, 2003
    Assignee: Immunex Corporation
    Inventor: Jeffrey T. McGrew
  • Patent number: 6596514
    Abstract: There are disclosed nucleotide sequences which can improve expression of recombinant proteins two- to eight-fold in stable cell pools when present in an expression vector.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: July 22, 2003
    Assignee: Immunex Corporation
    Inventors: Arvia E. Morris, James N. Thomas
  • Patent number: 6562949
    Abstract: The invention is directed to VESPR polypeptides as a purified and isolated protein, the DNA encoding the VESPR polypeptide, host cells transfected with cDNAs encoding VESPR, and methods for preparing VESPR polypeptides.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: May 13, 2003
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Michael R. Comeau, Robert F. DuBose, Richard S. Johnson
  • Patent number: 6555520
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: April 29, 2003
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
  • Patent number: 6492140
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: December 10, 2002
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • Patent number: 6492496
    Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation. In addition, antibodies specific to 2F1 polypeptide are provided.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: December 10, 2002
    Assignee: Immunex Corporation
    Inventors: Patricia Parnet, John E. Sims
  • Patent number: 6458350
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: October 1, 2002
    Assignee: Immunex Corporation
    Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
  • Patent number: 6451760
    Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: September 17, 2002
    Assignee: Immunex Corporation
    Inventors: Patricia Parnet, John E. Sims